No Data
No Data
RBC Capital Maintains Editas Medicine(EDIT.US) With Hold Rating, Maintains Target Price $8
Editas Medicine (EDIT) Receives a Hold From RBC Capital
JonesTrading Initiates Editas Medicine(EDIT.US) With Buy Rating, Announces Target Price $13
Editas Medicine, Inc. (EDIT) Presents at Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
Editas Medicine to Participate in Upcoming Investor Conferences
Editas Medicine, Inc. (NASDAQ:EDIT) Looks Inexpensive After Falling 32% But Perhaps Not Attractive Enough
No Data
No Data